AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$294.55−0.48 (-0.16%)
Close on Nov 16, 2026Market cap $520.50BP/E 83.2Yield 2.26%
AbbVie cash
Cash and short-term investments held at the end of each period.
AbbVie's cash was $6.57B at Jun 30, 2026. For fiscal 2025 it was $5.26B, down 5.4% from the year before. Over ten years it grew -4.6% a year on average. The highest annual figure on record is $39.92B in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.26B | -5.4% |
| FY2024 | Dec 31, 2024 | $5.56B | -56.7% |
| FY2023 | Dec 31, 2023 | $12.82B | +38.9% |
| FY2022 | Dec 31, 2022 | $9.23B | -6.1% |
| FY2021 | Dec 31, 2021 | $9.83B | +15.9% |
| FY2020 | Dec 31, 2020 | $8.48B | -78.8% |
| FY2019 | Dec 31, 2019 | $39.92B | +395.3% |
| FY2018 | Dec 31, 2018 | $8.06B | -17.7% |
| FY2017 | Dec 31, 2017 | $9.79B | +52.4% |
| FY2016 | Dec 31, 2016 | $6.42B | -23.6% |
| FY2015 | Dec 31, 2015 | $8.41B | +0.4% |
| FY2014 | Dec 31, 2014 | $8.37B | -15.4% |
| FY2013 | Dec 31, 2013 | $9.90B | +24.1% |
| FY2012 | Dec 31, 2012 | $7.98B | +29440.7% |
| FY2011 | Dec 31, 2011 | $27.00M | +170.0% |
| FY2010 | Dec 31, 2010 | $10.00M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.57B | +1.6% |
| Q1 FY2026 | Mar 31, 2026 | $9.39B | +81.4% |
| Q4 FY2025 | Dec 31, 2025 | $5.26B | -5.4% |
| Q3 FY2025 | Sep 30, 2025 | $5.67B | -22.2% |
| Q2 FY2025 | Jun 30, 2025 | $6.47B | -50.8% |
| Q1 FY2025 | Mar 31, 2025 | $5.18B | -71.4% |
| Q4 FY2024 | Dec 31, 2024 | $5.56B | -56.7% |
| Q3 FY2024 | Sep 30, 2024 | $7.29B | -45.2% |
| Q2 FY2024 | Jun 30, 2024 | $13.16B | +50.1% |
| Q1 FY2024 | Mar 31, 2024 | $18.07B | +168.8% |
| Q4 FY2023 | Dec 31, 2023 | $12.82B | +38.9% |
| Q3 FY2023 | Sep 30, 2023 | $13.29B | +11.9% |
| Q2 FY2023 | Jun 30, 2023 | $8.77B | -12.0% |
| Q1 FY2023 | Mar 31, 2023 | $6.72B | -11.2% |
| Q4 FY2022 | Dec 31, 2022 | $9.23B | -6.1% |
| Q3 FY2022 | Sep 30, 2022 | $11.88B | -3.0% |
| Q2 FY2022 | Jun 30, 2022 | $9.96B | +15.8% |
| Q1 FY2022 | Mar 31, 2022 | $7.57B | -22.6% |
| Q4 FY2021 | Dec 31, 2021 | $9.83B | +15.9% |
| Q3 FY2021 | Sep 30, 2021 | $12.25B | +54.1% |
| Q2 FY2021 | Jun 30, 2021 | $8.60B | +42.4% |
| Q1 FY2021 | Mar 31, 2021 | $9.78B | -76.2% |
| Q4 FY2020 | Dec 31, 2020 | $8.48B | -78.8% |
| Q3 FY2020 | Sep 30, 2020 | $7.95B | -25.3% |
| Q2 FY2020 | Jun 30, 2020 | $6.04B | +11.5% |
| Q1 FY2020 | Mar 31, 2020 | $41.14B | +687.0% |
| Q4 FY2019 | Dec 31, 2019 | $39.92B | +395.3% |
| Q3 FY2019 | Sep 30, 2019 | $10.65B | +21.2% |
| Q2 FY2019 | Jun 30, 2019 | $5.42B | +44.7% |
| Q1 FY2019 | Mar 31, 2019 | $5.23B | -44.8% |
| Q4 FY2018 | Dec 31, 2018 | $8.06B | -17.7% |
| Q3 FY2018 | Sep 30, 2018 | $8.79B | -8.0% |
| Q2 FY2018 | Jun 30, 2018 | $3.74B | -48.0% |
| Q1 FY2018 | Mar 31, 2018 | $9.47B | +51.6% |
| Q4 FY2017 | Dec 31, 2017 | $9.79B | +52.4% |
| Q3 FY2017 | Sep 30, 2017 | $9.55B | +20.2% |
| Q2 FY2017 | Jun 30, 2017 | $7.21B | – |
| Q1 FY2017 | Mar 31, 2017 | $6.25B | – |
| Q4 FY2016 | Dec 31, 2016 | $6.42B | – |
| Q3 FY2016 | Sep 30, 2016 | $7.95B | – |
See a number that looks wrong?